Ninlaro can be prescribed at general hospitals

Listed in March as an RSA refund type, passed through DC for major soldiers including Big 5

Contributing to patient daily maintenance

Ninlaro, an oral multiple myeloma treatment that solves the problem of insurance benefits, is prescribed at general hospitals.

 

According to related industries, Ninlaro (Ixazomib), an oral medication option in the field of multiple myeloma (MM), is used in Korea, including Samsung Medical Center, Seoul National University Hospital, the Catholic University of Korea Seoul St.

 

Mary's Hospital, Hwasun Chonnam National University Hospital, Kyungpook National University Hospital, Pusan ​​National University Hospital, and Chungnam National University Hospital.

 

it has passed the drug commitee (DC) of major medical institutions nationwide.

 

Ninlaro was designated as an orphan drug in May 2017 and was listed last month.

 

This is because the risk sharing agreement (RSA) could not be used due to the selection of competing drugs.

 

Takeda Korea, a supplier, has also provided free domestic supply since October 2019.

 

This drug, a proteasome inhibitor, proved its efficacy in the TOURMALINE-MM1 study, a phase 3 clinical trial in 722 patients with relapsed or refractory multiple myeloma.

 

According to the results of the study, Ninlaro, Revlimid (Lenalidomide), and Dexamethasone therapy had an average progression-free survival (PFS) of 20.6 months, which was higher than that of placebo, Lenalidomide and dexamethasone combination therapy at 14.7 months.

 

Meanwhile, three-drug therapy including Revlimid for multiple myeloma is recommended as a major treatment option in the NCCN guidelines and ESMO.

 

Reblimide's 'R' is the backbone of these three-drug therapies.

 

Amgen's Kyprolis (Carfilzomib) is used as KRd (Kyprolis, Revlimid, dexamethasone) therapy, BMS' Empliciti (Elotuzumab) is used as ERd therapy, Ninlaro is used as IRd therapy, Janssen's Darzalex (Daratumumab) is used as DRd therapy.

 

Deok-Hyun Yoon, professor of oncology at Asan Medical Center, said, "Multiple myeloma with many elderly patients and frequent recurrence will gradually increase in number of patients and increase the socioeconomic burden as the population ages.

 

In the treatment of relapsed and refractory multiple myeloma patients for a long period of time," "The treatment strategy that keeps this from progressing is important, and one of the factors to consider for this is patient compliance." He added, “The combination therapy of oral three-drugs through Ninlaro is a treatment option that lowers the patient's treatment burden for outpatient and administration time and increases medication convenience.

 

It is recommended for patients first.”